Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection

Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- <scp>d</scp> -Glucan Synthase: Implication for the Existing Susceptibility Breakpoint A Ser678Pro Substitution in Fks1p Confers Resistance to Echinocandin Drugs in Aspergillus fumigatus Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis , Candida orthopsilosis , and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility Assessment of the In Vitro Kinetic Activity of Caspofungin against Candida glabrata